To determine the diagnostic efficacy of CPT1A, we performed ROC curve analysis and compared the AUC, sensitivity, and specificity of CPT1A and three conventional clinically used biomarkers, CA15–3, CEA, and CA125, in breast cancer samples and healthy subjects. Here, MUC16 is linked to breast cancer.